Please login to the form below

Not currently logged in
Email:
Password:

Abbott sues J&J over Simponi

Abbott laboratories has sued Johnson & Johnson over its drug Simponi, stating that preparations to market the drug infringe a patent issued for Humira

Abbott laboratories has sued Johnson & Johnson over its drug Simponi, stating that preparations to market the drug infringe a patent issued for Humira.

Abbott's Humira (adalimumab), which treats rheumatoid arthritis, was issued a patent in 2007. Johnson & Johnson's Centocor unit plans to introduce golimumab, a new and competing drug for the crippling disease under the brand name Simponi.

Abbott is seeking cash compensation and an order to prevent further use of its invention by Johnson & Johnson.

Scott Stoffell, Abbott's spokesperson explained: "We're not asking the court to prevent the launch of Simponi. Abbott has no plans to file for a preliminary injunction or a temporary restraining order."

In response, Brian Kenney of Johnson & Johnson's Centocor unit said: "We are currently reviewing the complaint and will vigorously contest it… We believe we have rights to all of the intellectual property we need to market Simponi."

Johnson & Johnson received approval from the Food and Drug Administration (FDA) to market the anti-TNF-alpha therapy for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis in April 2009. The drug, to be co-marketed outside the US by Schering-Plough, will compete with Humira and Amgen's Enbrel.

5th May 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

Beyond the event
...
Anthill Agency and Actando partnership to Transform Pharma's Digital Skills
Anthill Agency, a leading life sciences digital agency, today announced the launch of the Anthill Academy™ and partnership with Actando's PharmAcademy....
Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...

Infographics